{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T04:02:20Z","timestamp":1788321740044,"version":"build-2803163510"},"reference-count":16,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2010,7,16]],"date-time":"2010-07-16T00:00:00Z","timestamp":1279238400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2010,10]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold><jats:styled-content>Purpose:<\/jats:styled-content>\u2002<\/jats:bold> To evaluate the long\u2010term efficacy and safety of once daily eslicarbazepine acetate (ESL) as adjunctive therapy for partial\u2010onset seizures in adults with epilepsy.<\/jats:p><jats:p><jats:bold><jats:styled-content>Methods:<\/jats:styled-content>\u2002<\/jats:bold> One\u2010year open\u2010label treatment extension with ESL in patients who completed a placebo\u2010controlled pivotal study (<jats:italic>Epilepsia<\/jats:italic> 2009; 50: 454\u2013463). Starting dose was 800\u2003mg once daily, for 4\u2003weeks; thereafter, dose could be titrated up or down. Doses of concomitant antiepileptic drugs were to be kept stable.<\/jats:p><jats:p><jats:bold><jats:styled-content>Results:<\/jats:styled-content>\u2002<\/jats:bold> Overall, 314 patients were enrolled. The intent\u2010to\u2010treat population consisted of 312 patients, and 239 (76.6%) completed 1\u2003year of treatment. ESL median dose was 800\u2003mg once daily. Compared to baseline, median seizure frequency decreased by 39% during the first 4\u2003weeks and between 48% and 56% thereafter. The responder rate (\u226550% seizure reduction) was 41% during weeks 1\u20134 and, thereafter ranged between 48% and 53%. The proportion of seizure\u2010free patients per 12\u2010week interval ranged between 8.7% and 12.5%. Quality of life, as measured by the Quality of Life in Epilepsy Inventory\u201031 (QOLIE\u201031), and depressive symptoms, as measured by the Montgomery Asberg Depression Rating Scale (MADRS), improved significantly compared to baseline. Treatment\u2010emergent adverse events (TEAEs) were reported by 51% of patients. The most frequent TEAEs were headache (10%), dizziness (10%), diplopia (5%), and nasopharyngitis (5%). TEAEs were mostly (97%) of mild to moderate intensity. Eleven patients (3.5%) discontinued due to TEAEs. There were no results of laboratory tests raising safety concerns.<\/jats:p><jats:p><jats:bold><jats:styled-content>Discussion:<\/jats:styled-content>\u2002<\/jats:bold> Sustained therapeutic effect, favorable tolerability and safety, and an improvement in quality of life and depressive symptoms were observed during long\u2010term add\u2010on treatment of partial\u2010onset seizures in adults with once daily ESL.<\/jats:p>","DOI":"10.1111\/j.1528-1167.2010.02660.x","type":"journal-article","created":{"date-parts":[[2010,7,16]],"date-time":"2010-07-16T15:11:06Z","timestamp":1279293066000},"page":"1963-1969","source":"Crossref","is-referenced-by-count":90,"title":["Long\u2010term efficacy and safety of eslicarbazepine acetate: Results of a 1\u2010year open\u2010label extension study in partial\u2010onset seizures in adults with epilepsy"],"prefix":"10.1111","volume":"51","author":[{"given":"Peter","family":"Hal\u00e1sz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce A.","family":"Cramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danilo","family":"Hodoba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Cz\u0142onkowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alla","family":"Guekht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Maia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Elger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricio","family":"Soares\u2010da\u2010Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the BIA\u20102093\u2010301 Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,7,16]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nurt.2006.10.005"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/9781444316667.ch38"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.23-17-06826.2003"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm980627g"},{"issue":"7","key":"e_1_2_7_6_1","first-page":"424","article-title":"Efficacy and safety of eslicarbazepine acetate (ESL) as add\u2010on treatment in adults with refractory partial\u2010onset seizures: BIA\u20102093\u2010302 study","volume":"49","author":"Ben\u2010Menachem E","year":"2008","journal-title":"Epilepsia"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1998.tb01278.x"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2007.00984.x"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2008.01946.x"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.2009.01218.x"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(01)00231-5"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.134.4.382"},{"key":"e_1_2_7_13_1","unstructured":"PotschkaH PekcecA Soares\u2010da\u2010SilvaP. (2007)Inhibition of kindling progression by eslicarbazepine acetate and licarbazepine.Proceedings of the 27th International Epilepsy Congress Singapore:Abstract Book."},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awh682"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.10473"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2004.10.011"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410290404"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1528-1167.2010.02660.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1528-1167.2010.02660.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T21:24:55Z","timestamp":1698787495000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1528-1167.2010.02660.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,16]]},"references-count":16,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["10.1111\/j.1528-1167.2010.02660.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1528-1167.2010.02660.x","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7,16]]}}}